Lyssikatos Joseph P, Chief Scientific Officer at Enliven Therapeutics (ELVN), has demonstrated a clear selling bias in recent years, with no open-market purchases recorded since 2024 and 21 sales totaling over $6.1 million in proceeds. The transactions, concentrated entirely in ELVN shares, reveal a pattern of consistent divestment, with particularly heavy selling activity in early 2026. On January 8-9, 2026 alone, Lyssikatos sold shares worth approximately $3.4 million across four transactions, including a single $1.45 million sale on January 9. Earlier sales were smaller but frequent, with multiple disposals in September 2025 ($165,742), August 2025 ($248,216), and July 2025 ($278,645).
The only non-sale transactions in the dataset involve awards (coded "A") with zero reported value on February 12, 2026, and February 13, 2024, alongside a single $13,440 market purchase ("M") on February 29, 2024. This purchase is dwarfed by the $197,006 in concurrent sales that same day. The absence of any recent buying activity, coupled with the scale and frequency of sales—including multiple six-figure disposals monthly since mid-2025—suggests a sustained reduction in Lyssikatos's ELVN position. The transactions collectively indicate a strategic shift away from equity accumulation, though the reasons remain undisclosed in the filings.
AI-assisted summary